Evidence map›Paper›PMID 37701836›Full record

ReviewPeerJ2023

The current landscape of m6A modification in urological cancers.

Yaohui Zeng, Cai Lv, Bangbei Wan, Binghao Gong

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in PeerJ, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Yaohui ZengDepartment of Urology, Central South University Xiangya School of Medicine Affiliated Haikou Hospital, Haikou, China.
Cai LvDepartment of Urology, Central South University Xiangya School of Medicine Affiliated Haikou Hospital, Haikou, China.
Bangbei WanDepartment of Urology, Central South University Xiangya School of Medicine Affiliated Haikou Hospital, Haikou, China.
Binghao GongDepartment of Urology, Central South University Xiangya School of Medicine Affiliated Haikou Hospital, Haikou, China.
Central South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

N6-methyladenosine (m6A) methylation is a dynamic and reversible procession of epigenetic modifications. It is increasingly recognized that m6A modification has been involved in the tumorigenesis, development, and progression of urological tumors. Emerging research explored the role of m6A modification in urological cancer. In this review, we will summarize the relationship between m6A modification, renal cell carcinoma, bladder cancer, and prostate cancer, and discover the biological function of m6A regulators in tumor cells. We will also discuss the possible mechanism and future application value used as a potential biomarker or therapeutic target to benefit patients with urological cancers.

Indexed as

Kidney NeoplasmsProstatic NeoplasmsUrinary Bladder NeoplasmsUrologic NeoplasmsAdenosineHumansMaleAdenosineBladder cancerEpigenetic modificationsN6-methyladenosineProstate cancerRenal cell carcinomaUrological cancer

Identifiers

PMID37701836
PMCPMC10493088
OpenAlexW4386514535

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.